QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VIII PASS Results, Reporting and Regulatory Follow-up

Test your understanding of the concepts covered by GVP Module VIII: PASS Results, Reporting and Regulatory Follow-up.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A study result indicates that a variation may be needed. What is the correct conceptual sequence?

The study result directly amends the marketing authorisation. The MAH first assesses the impact and then uses the applicable regulatory procedure to implement any required change. The vendor changes the marketing authorisation through the final report. The product information is changed without regulatory submission because the evidence is already public.

Question 2 of 10 A PASS reaches its planned endpoint but leaves substantial uncertainty because outcome ascertainment was incomplete. Which follow-up is most appropriate?

Declare the safety question resolved because the study is formally complete. Identify the remaining uncertainty and consider evidence generation designed to address the specific limitation. Remove the limitation from the final conclusion to avoid undermining the study. Repeat the same study design without considering why the first study was inconclusive.

Question 3 of 10 A PASS result conflicts with findings from spontaneous reports and clinical studies. What should the MAH do first?

Select the evidence source with the largest sample size. Assume that the PASS disproves all earlier evidence. Compare the sources on population, exposure, outcome definition, follow-up, confounding, missingness and design before integrating the evidence. Discard the PASS because spontaneous reports are part of routine pharmacovigilance.

Question 4 of 10 Why should a PASS result be assessed alongside spontaneous reports, literature and other evidence sources?

Because PASS results have no value unless confirmed by spontaneous reports Because the PASS is one component of the cumulative safety evaluation and may strengthen, weaken or refine an existing concern Because regulatory authorities require all evidence sources to produce identical results Because the final study report cannot contain its own scientific conclusion

Question 5 of 10 Which feature most strongly demonstrates that a final PASS report is scientifically traceable?

A large number of tables and figures A conclusion linked through the population, dataset, analysis, results and limitations to the protocol objective A conclusion written by an external statistician A report that excludes protocol deviations to avoid confusing the reader

Question 6 of 10 A PASS produces an unexpected association that was not part of its primary objective. What is the most appropriate interpretation?

The unexpected association automatically replaces the original primary objective. The finding should be disregarded because it was outside the protocol objective. The finding should be assessed as potentially important while keeping it distinct from the question the study was designed to answer. The finding should be included only in the statistical appendix and excluded from the conclusion.

Question 7 of 10 Which sequence best represents a defensible interpretation of PASS results?

Statistical significance, regulatory action, protocol review, uncertainty assessment Protocol objective, evidence actually generated, remaining uncertainty, justified conclusion Conclusion, data collection, protocol deviation assessment, primary objective Regulatory outcome, MAH opinion, study conduct, analytical dataset

Question 8 of 10 A primary-data-collection PASS identifies individual suspected adverse reactions. Which statement best reflects the required interface with pharmacovigilance operations?

The cases remain exclusively in the research database until study closure. The cases are subject to applicable adverse-reaction requirements and should be recorded and summarised in interim and final study reporting. The cases are excluded because PASS data cannot be used for individual case processing. Only events judged unrelated to the medicine require processing.

Question 9 of 10 A regulatory commitment is linked to an imposed PASS. Which event alone is insufficient to demonstrate closure of the commitment?

Documented completion of required implementation activities Resolution of outstanding authority questions Locking the study database and approving the final report Verification that downstream obligations have been addressed

Question 10 of 10 For an imposed non-interventional PASS, which milestone is most directly relevant to determining whether the final analytical dataset is available?

The date on which the study team holds its close-out meeting The date on which all vendor invoices are paid The availability of the dataset needed for analyses leading to the primary study results The date on which the database was first opened

Knowledge Assessment: GVP Module VIII PASS Results, Reporting and Regulatory Follow-up

Cookie Settings